157 related articles for article (PubMed ID: 9820503)
1. Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Blank M; George J; Barak V; Tincani A; Koike T; Shoenfeld Y
J Immunol; 1998 Nov; 161(10):5303-12. PubMed ID: 9820503
[TBL] [Abstract][Full Text] [Related]
2. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins.
Krause I; Blank M; Sherer Y; Gilburd B; Kvapil F; Shoenfeld Y
Eur J Immunol; 2002 Dec; 32(12):3414-24. PubMed ID: 12432572
[TBL] [Abstract][Full Text] [Related]
3. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.
Blank M; Krause I; Fridkin M; Keller N; Kopolovic J; Goldberg I; Tobar A; Shoenfeld Y
J Clin Invest; 2002 Mar; 109(6):797-804. PubMed ID: 11901188
[TBL] [Abstract][Full Text] [Related]
4. Immunization of naive BALB/c mice with human beta2-glycoprotein I breaks tolerance to the murine molecule.
Tincani A; Gilburd B; Abu-Shakra M; Blank M; Allegri F; Ottaviani R; Riboni M; Meroni PL; Balestrieri G; Shoenfeld Y
Arthritis Rheum; 2002 May; 46(5):1399-404. PubMed ID: 12115248
[TBL] [Abstract][Full Text] [Related]
5. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.
Chung Y; Lee SH; Kim DH; Kang CY
J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078
[TBL] [Abstract][Full Text] [Related]
6. Tolerogenic dendritic cells specific for β2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome.
Zandman-Goddard G; Pierangeli SS; Gertel S; Blank M
J Autoimmun; 2014 Nov; 54():72-80. PubMed ID: 24972993
[TBL] [Abstract][Full Text] [Related]
7. Induction of low dose oral tolerance in IL-10 deficient mice with experimental autoimmune encephalomyelitis.
Gonnella PA; Waldner HP; Kodali D; Weiner HL
J Autoimmun; 2004 Nov; 23(3):193-200. PubMed ID: 15501390
[TBL] [Abstract][Full Text] [Related]
8. Linseed oil suppresses the anti-beta-2-glycoprotein-I in experimental antiphospholipid syndrome.
Reifen R; Amital H; Blank M; Sklan D; Berkovich Z; Gershwin E; Shoenfeld Y
J Autoimmun; 2000 Nov; 15(3):381-5. PubMed ID: 11040078
[TBL] [Abstract][Full Text] [Related]
9. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity.
Sheng Y; Kandiah DA; Krilis SA
J Immunol; 1998 Aug; 161(4):2038-43. PubMed ID: 9712077
[TBL] [Abstract][Full Text] [Related]
10. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4⁺ T cell response to β2GPI.
Torres-Aguilar H; Blank M; Kivity S; Misgav M; Luboshitz J; Pierangeli SS; Shoenfeld Y
Ann Rheum Dis; 2012 Jan; 71(1):120-8. PubMed ID: 21914629
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance.
Chung Y; Chang SY; Kang CY
J Immunol; 1999 Oct; 163(7):3692-8. PubMed ID: 10490964
[TBL] [Abstract][Full Text] [Related]
12. β2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3β expression and reduces experimental-antiphospholipid-syndrome.
Blank M; Baraam L; Eisenstein M; Fridkin M; Dardik R; Heldman Y; Katchalski-Katzir E; Shoenfeld Y
J Autoimmun; 2011 Aug; 37(1):8-17. PubMed ID: 21524885
[TBL] [Abstract][Full Text] [Related]
13. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
[TBL] [Abstract][Full Text] [Related]
14. Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model.
Bourhim M; Darnige L; Legallais C; Arvieux J; Cevallos R; Pouplard C; Vijayalakshmi MA
J Mol Recognit; 2003; 16(3):125-30. PubMed ID: 12833567
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
16. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals.
Hattori N; Kuwana M; Kaburaki J; Mimori T; Ikeda Y; Kawakami Y
Arthritis Rheum; 2000 Jan; 43(1):65-75. PubMed ID: 10643701
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta induced by oral tolerance ameliorates experimental tracheal eosinophilia.
Haneda K; Sano K; Tamura G; Sato T; Habu S; Shirato K
J Immunol; 1997 Nov; 159(9):4484-90. PubMed ID: 9379048
[TBL] [Abstract][Full Text] [Related]
18. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
[TBL] [Abstract][Full Text] [Related]
19. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Blank M; Faden D; Tincani A; Kopolovic J; Goldberg I; Gilburd B; Allegri F; Balestrieri G; Valesini G; Shoenfeld Y
J Autoimmun; 1994 Aug; 7(4):441-55. PubMed ID: 7980847
[TBL] [Abstract][Full Text] [Related]
20. Priming or tolerization of the B- and Th2-dependent immune response by the oral administration of OVA-DNP is determined by the antigen dosage.
Franco L; Benedetti R; Ferek GA; Massouh E; Fló J
Cell Immunol; 1998 Nov; 190(1):1-11. PubMed ID: 9826441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
